MAZE - Maze Therapeutics, Inc.

26.5
0.810   3.057%

Share volume: 2,220,577
Last Updated: 04-22-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.23%

PREVIOUS CLOSE
CHG
CHG%
$25.69
0.81
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.27%
1 Month
-45.92%
3 Months
-40.14%
6 Months
-11.37%
1 Year
177.49%
2 Year
66.14%
Key data
Stock price
$26.50
P/E Ratio 
N/A
DAY RANGE
$26.00 - $29.08
EPS 
-$2.28
52 WEEK RANGE
$7.16 - $53.65
52 WEEK CHANGE
$244.16
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$1,231,878
AVERAGE 30 VOLUME 
$1,454,182
Company detail
CEO: Jason Coloma
Region: US
Website: mazetx.com
Employees: 121
IPO year: 2025
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Recent news